

WEDNESDAY, 15th FEBRUARY 2017 COMMENCING 9:30 AM AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

Enclosure

- 1. Welcome and introduction
- 2. Apologies
- 3. **Declarations of interest**
- 4. Minutes of previous meeting

1/AWMSG/0217

To protect commercial confidentiality the following appraisal will be held in private

5. Appraisal 1: Full Submission (PAS)
Aflibercept (Eylea®) for the treatment of adult patients with visual impairment due to myopic choroidal neovascularisation

2/AWMSG/0217 Appendices

The meeting will now open to the public (approximately 10.30am)

- 6. Chairman's report (verbal update)
- 7. Feedback from AWPAG Meeting held 14th December 2016

3/AWMSG/0217

8. National Prescribing Indicators 2016–2017 – Analysis of Prescribing Data to September 2016

4/AWMSG/0217

9. National Prescribing Indicators 2017–2018

5/AWMSG/0217

10. National Prescribing Indicators 2017–2018 – Supporting Information for Prescribers

6/AWMSG/0217

11. Appraisal 2: Full Submission

Human alpha1-proteinase inhibitor (Respreeza®) for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ).

7/AWMSG/0217 Appendices

12. Appraisal 3: Limited Submission

Triptorelin (Decapeptyl® SR) as adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. As neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.

8/AWMSG/0217 Appendices 13. Medicines Management Resource for Chronic Kidney Disease 9/AWMSG/0217

14. CEPP National Audit: Medicines Management for Chronic Kidney Disease

10/AWMSG/0217

Date of next meeting – 15th March 2017 in Abergavenny